3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
18
Phase 3
12
Phase 1
11
Phase 1/2
7
Phase 4
2
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
8
NIH
2
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Cisplatin
29
Carboplatin
28
Gemcitabine
27
Paclitaxel
26
pembrolizumab
24
Capecitabine
16
Pemetrexed
15
Bevacizumab
15
Docetaxel
14
Oxaliplatin
13
Fluorouracil
12
Drug Therapy
12
Nivolumab
10
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
anlotinib
7
Injections
7
Rituximab
6
venetoclax
5
atezolizumab
5
Temozolomide
5
Leucovorin
5
Ipilimumab
5
Lenalidomide
4
Irinotecan
4
Interferon alpha-2
4
Folfox protocol
4
Dexamethasone
4
Azacitidine
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
INDUSTRY
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT05139017
2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
290 enrolled